Minghong Bi

3.9k total citations
17 papers, 328 citations indexed

About

Minghong Bi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Minghong Bi has authored 17 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Minghong Bi's work include Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). Minghong Bi is often cited by papers focused on Lung Cancer Treatments and Mutations (7 papers), Lung Cancer Research Studies (5 papers) and Colorectal Cancer Treatments and Studies (3 papers). Minghong Bi collaborates with scholars based in China and South Korea. Minghong Bi's co-authors include Jingru Yang, Yaping Wang, Jingjing Zhang, Zhe Liu, Guoping Sun, Xiao Han, Hao Liu, Haoran Zhang, Zhenyuan Gao and Shanshan Zhang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Minghong Bi

16 papers receiving 324 citations

Peers

Minghong Bi
Sahar Pakneshan Australia
Zhi‐Gang Sun China
Bamidele Adesunloye United States
Jiannan Yao China
Heather Symecko United States
Franziska M. Ippen Germany
Julie Jones United States
Jennifer Inra United States
Tobias S. Slørdahl Norway
Gerald C Hsu United States
Sahar Pakneshan Australia
Minghong Bi
Citations per year, relative to Minghong Bi Minghong Bi (= 1×) peers Sahar Pakneshan

Countries citing papers authored by Minghong Bi

Since Specialization
Citations

This map shows the geographic impact of Minghong Bi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Minghong Bi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Minghong Bi more than expected).

Fields of papers citing papers by Minghong Bi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Minghong Bi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Minghong Bi. The network helps show where Minghong Bi may publish in the future.

Co-authorship network of co-authors of Minghong Bi

This figure shows the co-authorship network connecting the top 25 collaborators of Minghong Bi. A scholar is included among the top collaborators of Minghong Bi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Minghong Bi. Minghong Bi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Zhang, Xiaochun, Xingya Li, Minghong Bi, et al.. (2023). Phase Ib/IIa study assessing the safety and efficacy of AL8326 monotherapy in patients with ≥3rd line small cell lung cancer (SCLC) treatment.. Journal of Clinical Oncology. 41(16_suppl). 8585–8585. 1 indexed citations
3.
Chu, Tianqing, Jun Lü, Minghong Bi, et al.. (2021). Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. Cancer Biology and Medicine. 18(3). 816–824. 23 indexed citations
4.
Pan, Yueyin, Yingying Du, Yong Wang, et al.. (2021). A clinical study of camrelizumab combined with chemotherapy and sequential apatinib in the second-line treatment of patients with advanced non-small cell lung cancer.. Journal of Clinical Oncology. 39(15_suppl). e21051–e21051. 3 indexed citations
5.
Gu, Kangsheng, Minghong Bi, Dong Zhao, et al.. (2021). A real-world study of camrelizumab in the treatment of advanced lung cancer patients.. Journal of Clinical Oncology. 39(15_suppl). e21056–e21056.
6.
Shi, Yuankai, Qiqing Cai, Yu Jiang, et al.. (2020). Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study. Clinical Cancer Research. 26(24). 6445–6452. 26 indexed citations
7.
Bi, Minghong, et al.. (2020). Downregulation of NEAT1 Suppresses Cell Proliferation, Migration, and Invasion in NSCLC Via Sponging miR-153-3p. Cancer Biotherapy and Radiopharmaceuticals. 35(5). 362–370. 18 indexed citations
8.
Zhang, Shanshan & Minghong Bi. (2020). The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis. Annals of Palliative Medicine. 9(6). 4081–4088. 9 indexed citations
9.
Bi, Minghong, et al.. (2019). Comparison of case-based learning and traditional method in teaching postgraduate students of medical oncology. Medical Teacher. 41(10). 1124–1128. 118 indexed citations
10.
Bi, Minghong, Haoran Zhang, Huazhang Wu, et al.. (2019). Effect of inhibiting ACAT‑1 expression on the growth and metastasis of Lewis lung carcinoma. Oncology Letters. 18(2). 1548–1556. 21 indexed citations
11.
Bi, Minghong, et al.. (2018). Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review. OncoTargets and Therapy. Volume 11. 883–890. 3 indexed citations
12.
13.
Liu, Zhe, Minghong Bi, Jingjing Zhang, et al.. (2016). Metformin induces apoptosis via a mitochondria-mediated pathway in human breast cancer cells in vitro. Experimental and Therapeutic Medicine. 11(5). 1700–1706. 71 indexed citations
14.
Wang, Yaping, et al.. (2016). Apatinib in gastric carcinoma: A case report of partial response for first‐line treatment in advanced disease. Asia-Pacific Journal of Clinical Oncology. 13(5). e528–e530. 3 indexed citations
15.
Gao, Zhenyuan, et al.. (2015). SRPX2 promotes cell migration and invasion via FAK dependent pathway in pancreatic cancer.. International Journal of Clinical and Experimental Pathology. 8(5). 4791–8. 20 indexed citations
16.
Bi, Minghong, et al.. (2014). [Research progress of HGF/MET signaling pathway in EGFR-TKI resistance 
in non-small cell lung cancer].. SHILAP Revista de lepidopterología. 17(10). 755–9. 4 indexed citations
17.
Han, Wei & Minghong Bi. (2013). [Clinical meaning of EML4-ALK fusion gene in non-small cell lung cancer].. SHILAP Revista de lepidopterología. 16(2). 97–101. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sahar Pakneshan Breakdown of academic impact, for papers by Zhi‐Gang Sun Breakdown of academic impact, for papers by Bamidele Adesunloye Breakdown of academic impact, for papers by Jiannan Yao Breakdown of academic impact, for papers by Heather Symecko Breakdown of academic impact, for papers by Franziska M. Ippen Breakdown of academic impact, for papers by Julie Jones Breakdown of academic impact, for papers by Jennifer Inra Breakdown of academic impact, for papers by Tobias S. Slørdahl Breakdown of academic impact, for papers by Gerald C Hsu
Rankless by CCL
2026